Overview

* Viridian Q3 revenue rise driven by license and collaboration revenue

* Company secured up to $889 mln in financing, enhancing cash position to $887.9 mln

* Submitted BLA for veligrotug to FDA, commercial launch expected mid-2026 if approved

Outlook

* Viridian expects veligrotug U.S. commercial launch in mid-2026, pending FDA approval

* Company anticipates VRDN-003 topline data in Q1 and Q2 2026

* Viridian believes cash and potential revenues will fund plans through profitability

Result Drivers

* Research and development expenses were $86.3 million during the three months ended September 30, 2025, compared to $69.2 million during the three months ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $70 mln

Revenue

Q3 Net -$34.59

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Viridian Therapeutics Inc ( VRDN ) is $37.50, about 39.9% above its November 4 closing price of $22.55

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)